key: cord-0682621-wwje5srb authors: Nishikimi, Akihiko; Watanabe, Ken; Watanabe, Atsushi; Yasuoka, Mikako; Watanabe, Ryota; Oshima, Hironori; Kitagawa, Yuichi; Tokuda, Haruhiko; Niida, Shumpei; Kojima, Masayo title: Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan date: 2021-10-30 journal: J Infect DOI: 10.1016/j.jinf.2021.10.021 sha: cb875988edc8b79525f2e580b6b4f83a4533da18 doc_id: 682621 cord_uid: wwje5srb nan Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China, in late 2019, and the first identified case in Japan was in January 2020. 1 Later, the number of new cases began to increase exponentially in the middle of February, leading to a nationwide spread. 2, 3 Since then, Japan has faced five waves of the pandemic, each bigger than the last. The National Center for Geriatrics and Gerontology (NCGG) is one of the national centers for advanced and specialized medicine composed of a hospital and a research institute located in Aichi Prefecture, central Japan. Due to its roles in geriatric medicine, the center accepts many elderly patients, with a higher risk of mortality due to COVID-19. To investigate the cumulative SARS-CoV-2 infection rate among workers in the NCGG over time, we designed a repeated cross-sectional study to examine SARS-CoV-2 antibodies. We have previously reported the results of the baseline survey, a low seroprevalence of SARS-COV-2 (0.32%) in June 2020 (after the first wave). 4 In this paper, we report the results of the second survey using serum collected in June 2021(during and after the fourth wave). Out of 632 employees who participated in the 2020 survey, 556 agreed to participate in the second survey (participation rate, 88.0%). In June 2021, we asked the participants who provided written informed consent to answer an electronic questionnaire on sociographic and COVID-19-related factors. The institutional review board of the ethics and conflicts of interest committee approved this study (No, 1481). We measured the antibodies against SARS-CoV-2 nucleocapsid (N) and spike (S) protein to analyze the prevalence of naturally infected SARS-CoV-2. At the in-house laboratory, we performed chemiluminescence enzyme immunoassays with Sysmex SARS-CoV-2 N-IgG and S-IgG kits, which detect Immunoglobulin G (IgG) against N and S proteins, respectively. We also used Abbott SARS-CoV-2 assay to detect N protein-specific IgG. Additionally, electrochemiluminescence immunoassays were performed using the Roche Elecsys Anti-SARS-CoV-2 RUO system to detect total IgG-antibodies of N protein at the laboratory of SRL Inc. (Tokyo, Japan). Those who showed positive results in two or more tests were considered seropositive. Data were analyzed using SPSS for Windows (version 27.0, IBM). The difference between the baseline and the second-year surveys was examined with McNeamer's test. All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant. The total participant characteristics, the difference in the experiences related to COVID-19, and prevalence of seropositive cases against SARS-CoV-2 between the baseline and the second survey are summarized in Table 1 . Of 556 participants, the mean ± SD age was 42.0 ± 11.4 years, and 63.3% were female. The clinical staff, including doctors, nurses, and allied health care professionals, was 63.8%. Approximately 90% of the participants were vaccinated during the period between The present study indicates that the antibody against the specific epitopes of the N protein obtained through natural infection is possibly maintained for at least one year. Therefore, previous infection with SARS-CoV-2 infection could be estimated using antibody prevalence against N protein even in individuals with vaccination. A survey of the general population conducted by the Ministry of Health, Labor and Welfare of Japan, which used similar assays as this study, revealed that seroprevalence in December 2020 was 0.54% in Aichi, where NCGG is located. 5 Antibody prevalence of this study (0.54%) is almost equivalent to the 2021 survey. Also, we confirmed that mRNA vaccination is highly effective to increase anti-SARS-CoV-2-spike-binding antibody level. In conclusion, a regular survey of seroprevalence using multiple tests is effective to identify COVID-19 spread and monitor infection control measures in facilities. None Epidemiology of COVID-19 outbreak in Japan Overview of the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021 Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan Seroprevalence of antibodies against SARS-CoV-2 among workers in a national research institute and hospital in Central Japan About antibody prevalence survey The authors thank Megumi Banno, Hiroyuki Fujikawa, and Yukari Kido for their technical assistance. Fund (2020-B-09).